52545-13-8

Basic information

• Product Name: 2(1H)-Pyridinone,4-methoxy-(9CI)
• Synonyms: 2(1H)-Pyridinone,4-methoxy-(9CI);4-METHOXY-2(1H)-PYRIDINONE;4-Methoxy-2-pyridone4-METHOXY-2(1H)-PYRIDINONE;4-Methoxy-2-pyridone;4-Methoxy-1,2-dihydropyridin-2-one;4-Methoxypyridin-2-ol;4-Methoxypyridin-2(1H)
• CAS NO: 52545-13-8
• Molecular Formula: C₆H₇NO₂
• Molecular Weight: 125.126
• Product Categories: PYRIDINE
• Mol File: 52545-13-8.mol
• Article Data: 10

Chemical Properties

• Melting Point: 101-102 °C
• Boiling Point: 355.1oC at 760 mmHg
• Flash Point: 168.5oC
• Appearance: /
• Density: 1.16g/cm3
• Vapor Pressure: 3.21E-05mmHg at 25°C
• Refractive Index: 1.526
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 11.08±0.10(Predicted)
• CAS DataBase Reference: 2(1H)-Pyridinone,4-methoxy-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2(1H)-Pyridinone,4-methoxy-(9CI)(52545-13-8)
• EPA Substance Registry System: 2(1H)-Pyridinone,4-methoxy-(9CI)(52545-13-8)

Safety Data

• Hazardous Substances Data: 52545-13-8(Hazardous Substances Data)

Usage

General Description

2(1H)-Pyridinone,4-methoxy-(9CI) is a chemical compound with the molecular formula C6H7NO2. It is a derivative of pyridine and contains a methoxy group attached to the fourth carbon atom of the pyridine ring. 2(1H)-Pyridinone,4-methoxy-(9CI) is commonly used in the pharmaceutical industry as a building block for the synthesis of various bioactive molecules and pharmaceutical drugs. It has been found to possess a range of biological activities, including antiviral, antimicrobial, and antifungal properties. Additionally, 2(1H)-Pyridinone,4-methoxy-(9CI) has also been studied for its potential as an antioxidant and anti-inflammatory agent. Overall, this compound has promising applications in the field of medicinal chemistry and drug discovery.

InChI:InChI=1/C6H7NO2/c1-9-5-2-3-7-6(8)4-5/h2-4H,1H3,(H,7,8)

Upstream product

• 1122-96-9 4-methoxypyridine N-oxide 
• 1124-33-0 4-nitraminopyridine N-oxide 
• 870854-86-7 3-Methoxy-3-methyl-2-benzenesulfonylpropenenitrile 
• 870854-88-9 4-methoxy-3-(phenylsulfonyl)pyridin-2(1H)-one 
• 74-88-4 methyl iodide 
• 124049-09-8 2-acetoxy-4-methoxypyridine 
• 75608-94-5 5-methoxy-3-oxo-2-azabicyclo<2.2.0>hex-5-one 
• 620-08-6 4-methoxypyridine 
• 18677-43-5 2,4-dimethoxypyridine 

Downstream Products

• 171016-52-7 4-Methoxy-3-trimethylsilanyl-1H-pyridin-2-one 
• 17228-69-2 2-chloro-4-methoxy-pyridine 
• 1040112-28-4 3-[4-methoxy-2(1H)-pyridonyl]-N-phenylmaleimide 
• 175965-83-0 2-fluoro-4-methoxypyridine 
• 586373-19-5 1-benzyl-4-hydroxypyridin-2(1H)-one 
• 1429318-32-0 C₁₂H₁₁NO₂ 
• 108279-83-0 7-methoxy-5-oxo-1a,2,3,5,7a,7b-hexahydro-1H-cyclobutaindolizine 
• 171228-87-8 (1S,4S)-(-)-2-Hydroxymethyl-5-methoxy-3-oxo-2-azabicyclo<2.2.0>hex-5-ene 
• 388573-34-0 4-hydroxy-9-(4-methoxybenzylamino)-5-[2-(4-methoxybenzylamino)pyrimidin-4-yl]pyrido[3',2':4,5]pyrrolo[1,2-c]pyrimidine 
• 388573-33-9 4-methoxy-9-(4-methoxybenzylamino)-5-[2-(4-methoxybenzylamino)pyrimidin-4-yl]pyrido[3',2':4,5]pyrrolo[1,2-c]pyrimidine 
• 41759-19-7 4-methoxy-1-methyl-2-pyridone 
• 870854-92-5 1-benzyl-4-methoxypyridin-2(1H)-one 
• 82493-68-3 2-butyl-2-azabicyclo[2.2.0]hex-5-en-3-one 
• 82493-66-1 (1α,2β,5β,6α)-3,7-dibutyl-3,7-diazatricyclo[4.2.2.2^2,5]dodeca-9,11-diene-4,8-dione 

Relevant articles and documents

Photocycloadditions of 4-Methoxy-2-pyridone to Olefins and Synthesis of 1,2-Dihydrocyclobutapyridin-3(4H)-ones

Irradiation of 4-methoxy-2-pyridone (1) in acetone in the presence of electron-rich alkenes afforded the 3-azabicyclooct-4-en-2-ones (2a-c) as the major products, whereas photolyses in the presence of electron-deficient alkenes led to the 2-azabicyclooct-4-en-3-ones (4a,b) as the major products; base treatment of the former adducts gave rise to the novel 1,2-dihydrocyclobutapyridin-3(4H)-ones (3a-c).

INHIBITORS OF BRUTON'S TYROSINE KINASE

Disclosed herein are compounds that inhibit Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

COMPOUNDS AND METHODS OF USE

Selected compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.